ArticleBMC cancer2025
Prognostic utility of the C-reactive protein-albumin-lymphocyte (CALLY) index in metastatic renal cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Deciphering the potential of the C-reactive protein-albumin-lymphocyte index as a prognostic biomarker in malignancy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- The CALLY Index Is Associated with Overall Survival in Patients with De Novo Metastatic Gastric Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for Survival in Nivolumab-Treated Metastatic Renal Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Towards Precision Medicine in Metastatic Renal Cell Carcinoma: The Role of Emerging Biomarkers.Cancers · 2026Review
- Prognostic Value of the CALLY Index in Diffuse Large B-Cell Lymphoma: Linking Inflammation, Nutrition, and Tumor Biology.Cancers · 2026Article
- Prognostic Nutritional Index enhances risk stratification and predicts progression-free survival in upper tract urothelial carcinoma.Discover oncology · 2026Article
- The C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index as an Independent Predictor of Progression and Survival in Metastatic Renal Cell Carcinoma.Journal of clinical medicine · 2026Article
- Association and incremental predictive value of preoperative AISI and CALLY for postoperative pulmonary complications after McKeown esophagectomy following neoadjuvant chemoimmunotherapy.Frontiers in immunology · 2026Article
- Clinical Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte Index (CALLY) in Patients with Stage III Breast Cancer.Breast cancer (Dove Medical Press) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveThe CALLY index has been recognized as a prognostic biomarker across various malignancies; however, its prognostic utility in metastatic renal cell carcinoma (mRCC) has not been extensively characterized. This study aimed to elucidate the prognostic significance of the C-reactive protein-albumin-lymphocyte (CALLY) index in patients diagnosed with mRCC.
methodsIn this retrospective multicenter study, patients with metastatic renal cell carcinoma were included. Demographic and disease-related data were collected. The CALLY index was calculated as follows: serum albumin level (g/dL) × absolute lymphocyte count (cells/µL)/C-reactive protein (CRP) (mg/dL) × 10
resultsA total of 95 patients were included in the present study. The prognostic cut-off value for the CALLY index was determined as 0.12. The median overall survival (OS) was 11.1 months (95% CI 6.7-15.4) in the CALLY index < 0.12 group, compared to 45.7 months (95% CI 31.6-59.8) in the CALLY index ≥ 0.12 group (p < 0.001). Similarly, the median progression-free survival (PFS) was 7.1 months (95% CI 4.5-13.2) in the CALLY index < 0.12 group and 33.1 months (95% CI 17.2-48.1) in the CALLY index ≥ 0.12 group (p < 0.001). In Cox regression analysis, a CALLY index < 0.12 was identified as an independent prognostic factor for shorter OS (HR: 0.41, 95% CI 0.22-0.76, p = 0.004) and PFS (HR: 0.40, 95% CI 0.23-0.69, p = 0.001).
conclusionThe CALLY index was identified as an independent prognostic biomarker in metastatic renal cell carcinoma. Prospective large-scale studies are needed to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.